Given the significant effect of Dasatinib in the initial in vitro and in vivo studies (Fig. 2C-E, Supplementary Figure S2), we evaluated the pharmacological effect of Dasatinib on 2D cultures of TFE3-fusion RCC, and on Src activation and the activation of downstream pathway signaling proteins. The gene discussed is SRC; the disease is renal cell carcinoma.